Effect of Strontium Ranelate on Serum Leptin and Bone Turnover Markers in Women with Established Postmenopausal Osteoporosis

Basit Öğe Kaydı
dc.contributor.authorBayhan, Ilhan
dc.contributor.authorDogan, Nasuh U.
dc.contributor.authorOzaksit, Gulnur
dc.contributor.authorUygur, Dilek
dc.contributor.authorUgurlu, Nil
dc.contributor.authorUgur, Mustafa
dc.date.accessioned2020-03-26T18:41:38Z
dc.date.available2020-03-26T18:41:38Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOBJECTIVE: To assess the ass. ociation between leptin levels and bone mineral density (BMD) and bone metabolism markers in postmenopausal women taking strontium ranelate. STUDY DESIGN: In this longitudinal uncontrolled study, postmenopausal osteoporotic women were administered strontium ranelate and categorized into 1 of 2 groups: overweight and lean. BMD, serum leptin, bone -specific alkaline phosphatase (ALP) and urinary deoxypyridinoline (Dpd) were assessed at baseline, 6 and 12 months of the therapy. RESULTS: For all 47 women, leptin levels increased at the sixth month (p =0.001) and 1 year after treatment (p = 0.001), Dpd levels. decreased at the sixth month.(p = 0.001) and 1 year after treatment (p =0.003), but ALP levels did not change with respect to basal levels. Spine and hip BMD also increased at the end of 1 year (p =0.01 and p =0.001, respectively). For overweight women leptin levels increased 6 months and 1 year after treatment (p =0.003 and p =0.001, respectively). Dpd levels decreased significantly at the sixth month and at 1 year (p =0.001 and p = 0.041), but ALP levels did not change. Hip and spine BMD also increased (p =0.036 and p =0.002). The lean group had similar serum results and BMD scores after treatment. CONCLUSION: Our data supports a positive effect of leptin on bone metabolism in favor of bone resorption inhibition in postmenopausal osteoporotic women on strontium treatment.en_US
dc.identifier.endpage323en_US
dc.identifier.issn0024-7758en_US
dc.identifier.issn1943-3565en_US
dc.identifier.issue07.08.2020en_US
dc.identifier.pmid23947082en_US
dc.identifier.startpage319en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29422
dc.identifier.volume58en_US
dc.identifier.wosWOS:000209697300007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSCI PRINTERS & PUBL INCen_US
dc.relation.ispartofJOURNAL OF REPRODUCTIVE MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectbone resorptionen_US
dc.subjectleptinen_US
dc.subjectosteoporosisen_US
dc.subjectstrontium ranelateen_US
dc.titleEffect of Strontium Ranelate on Serum Leptin and Bone Turnover Markers in Women with Established Postmenopausal Osteoporosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu